The FDA Group’s Nick Capman speaks with Marwan Fathallah, President and CEO of DIA Global, for a wide-ranging discussion on what it takes to lead effectively across the life science product development cycle—from concept to commercialization.
With nearly 30 years of leadership experience spanning pharmaceuticals, medical devices, and diagnostics, Marwan has held senior roles in R&D, regulatory, clinical, scientific affairs, and operations. He brings a rare, holistic view of how leadership, culture, and systems thinking come together to drive successful outcomes in complex, regulated environments.
Their conversation explores how to balance innovation and compliance, structure cross-functional teams for consistent execution, and foster cultures that prioritize transparency, collaboration, and patient focus.
Marwan shares practical insights on:
How to balance innovation with scientific and regulatory rigor by embedding compliance early in R&D.
Building structured product development committees that unite R&D, regulatory, clinical, and commercial functions around shared goals.
Setting meaningful KPIs—focusing on leading indicators that predict success rather than lagging ones that only measure it.
The leadership traits that make collaboration work: communication, integrity, empathy, and systems thinking.
Managing conflict constructively and maintaining team health through transparency and accountability.
Keeping the patient at the center of every decision to align purpose across departments.
About The FDA Group
The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle—from clinical development to commercialization—with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations: https://www.thefdagroup.com/
Информация по комментариям в разработке